antiplatelets drug

A EFFACER - Aspirin - Atopaxar - Cangrelor - Clopidogrel - Dipyridamol - Elinogrel - Prasugrel - Sulfinpyrazone - Ticagrelor - Ticlopidine - Triflusal - Vorapaxar      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultNon fatal MIcardiovascular events

acute coronary syndrome

aspirin
ATACS-pilot, 1990   aspirincontrolnegative-100%-100%
Huddinge, 1988     aspirincontrolnegative
Frankfurt, 1976   aspirincontrolnegative12%
VA-pilot   aspirinplacebonegative-100%-77%
VA-main, 1983   aspirinplaceboLow risk of bias suggesting-44%-39%
RISC, 1990   aspirinplaceboLow risk of bias suggesting-48%-47%
ALDUSA-pilot   aspirinplacebonegative+Infini%250%
Théroux, 1988   aspirinplaceboLow risk of bias suggesting-72%-37%
Canadian (Aspirin vs PBO), 1985   aspirinplaceboLow risk of bias -
Dutch-aspirin, 1990     aspirinplaceboLow risk of bias negative-67%-33%
ISIS-pilot, 1987     aspirinplaceboLow risk of bias negative-24%-30%
ISIS-2, 1988   aspirinplaceboLow risk of bias suggesting-54%-26%
APRICOT, 1993   aspirinplaceboLow risk of bias suggesting-73%-70%
Canadian (Aspirin + sulfinpyrazone), 1985   aspirin + sulfinpyrazoneplaceboLow risk of bias negative15%-10%
atopaxar
J-LANCELOT, 2010   atopaxarplaceboExploratory -
LANCELOT ACS     atopaxarplaceboExploratory -
clopidogrel
COMMIT, 2005      NCTclopidogrelplaceboLow risk of bias suggesting-18%-8%
CLARITY-TIMI 28, 2005   clopidogrelplaceboLow risk of bias -
CURE, 2001     clopidogrel + aspirinaspirinLow risk of bias suggesting -18%
CURRENT OASIS 7 (clopidogrel), 2010    NCTclopidogrel high-dose regimenclopidogrel standard-doseLow risk of bias negative -6%
dipyridamol
Prandoni, 1991   aspirin + dipyridamolplaceboLow risk of bias negative-55%-45%
elinogrel
ERASE-MI, 2009     elinogrelplaceboLow risk of bias negative
prasugrel
TRILOGY ACS (overall population), 2012        NCTprasugrelclopidogrelLow risk of bias negative
TRITON-TIMI 38, 2007      NCTprasugrelclopidogrelLow risk of bias suggesting -24%
sulfinpyrazone
Dutch sulphinpyrazone, 1986   sulfinpyrazonecontrolnegative-50%
Canadian (sulfinpyrazone alone), 1985   sulfinpyrazoneplaceboLow risk of bias -
Wilcox, 1980   sulfinpyrazoneplacebonegative400%
Louvain sulphinpyrazone, 1983   sulfinpyrazoneplaceboLow risk of bias negative+Infini%
ticagrelor
PLATO, 2009      NCTticagrelorclopidogrelLow risk of bias suggesting-15%
DISPERSE-2 (90mg), 2007       ticagrelorclopidogrelLow risk of bias negative9%
ticlopidine
STAI, 1990   ticlopidinecontrolsuggesting-46%-48%
Knudsen-A, 1985   ticlopidinecontrolnegative
Florida UA   ticlopidineplacebonegative
trapidil
Modena   trapidilplacebosuggesting-79%-79%
triflusal
Plaza, 1993   triflusalplaceboLow risk of bias suggesting-66%-55%
vorapaxar
TRACER, 2011      NCTvorapaxarplacebo (on top standard therapy) Low risk of bias -

acute myocardial infarction

aspirin
Huddinge, 1988     aspirincontrolnegative
Frankfurt, 1976   aspirincontrolnegative12%
Dutch-aspirin, 1990     aspirinplaceboLow risk of bias negative-67%-33%
ISIS-pilot, 1987     aspirinplaceboLow risk of bias negative-24%-30%
ISIS-2, 1988   aspirinplaceboLow risk of bias suggesting-54%-26%
APRICOT, 1993   aspirinplaceboLow risk of bias suggesting-73%-70%
clopidogrel
COMMIT, 2005      NCTclopidogrelplaceboLow risk of bias suggesting-18%-8%
CLARITY-TIMI 28, 2005   clopidogrelplaceboLow risk of bias -
elinogrel
ERASE-MI, 2009     elinogrelplaceboLow risk of bias negative
sulfinpyrazone
Dutch sulphinpyrazone, 1986   sulfinpyrazonecontrolnegative-50%
Wilcox, 1980   sulfinpyrazoneplacebonegative400%
Louvain sulphinpyrazone, 1983   sulfinpyrazoneplaceboLow risk of bias negative+Infini%
ticlopidine
Knudsen-A, 1985   ticlopidinecontrolnegative

CABG surgery

aspirin
McEnany, 1982   aspirinplaceboLow risk of bias negative-100%-78%
Lorenz, 1984   aspirinplaceboLow risk of bias negative-100%-47%
GESIC (aspirin), 1990   aspirinplaceboLow risk of bias negative159%
Sydney, 1991   aspirinplaceboLow risk of bias -
Hockings, 1993   aspirinplaceboLow risk of bias -
clopidogrel
CASCADE, 2009      NCTclopidogrel+aspirinaspirinLow risk of bias -
dipyridamol
Pantely, 1979   aspirin + dipyridamolcontrolnegative
Brussels, 1987   aspirin + dipyridamolcontrolnegative-48%-31%
Czech, 1986   aspirin + dipyridamolcontrol -
Des Moines, 1980   aspirin + dipyridamolcontrol -
Toronto dipyridamole, 1987   dipyridamolcontrol -
Brooks, 1985     aspirin + dipyridamolplaceboLow risk of bias negative100%
Mayo-A, 1984   aspirin + dipyridamolplaceboLow risk of bias negative-15%
Wadsworth, 1985   aspirin + dipyridamolplaceboLow risk of bias negative59%
Basel, 1989   aspirin + dipyridamolplaceboLow risk of bias negative-100%-100%
Leeds-B, 1985   aspirin + dipyridamolplaceboLow risk of bias -
Thaulow, 1987   aspirin + dipyridamolplaceboLow risk of bias -
GESIC (aspirin+dipyridamol), 1990   aspirin + dipyridamolplaceboLow risk of bias negative81%
Ekestrom, 1990   dipyridamolplaceboLow risk of bias -
sulfinpyrazone
Baur, 1982     sulfinpyrazoneplaceboLow risk of bias -
sulotroban
German sulotroban, 1989   sulotrobancontrol -
ticlopidine
Zurich, 1982   ticlopidinecontrol -
Knudsen-B, 1983   ticlopidinecontrol -
Romeo, 1983   ticlopidinecontrol -
Kohn, 1990   ticlopidinecontrol -
Liège-I, 1984   ticlopidineplaceboLow risk of bias negative-100%
Liège-II, 1987   ticlopidineplaceboLow risk of bias negative-67%-51%

cardiovascular prevention

aspirin
JPAD, 2008      NCTaspirinno treatmentRisk of bias suggesting35%-20%
PPP (diabetics sub group), 2003   aspirinno treatmentExploratory negative-10%
British Doctor’s Trial, 1988   aspirinno treatmentprimary preventionRisk of bias negative-3%-2%
Primary Prevention Project, 2001     aspirinno treatmentprimary preventionRisk of bias negative -27%-28%
POPADAD aspirin, 2008     aspirinplaceboLow risk of bias negative-2%-1%
DAMAD, 1989   aspirinplaceboLow risk of bias negative 320%48%
ETDRS, 1992   aspirinplaceboLow risk of bias suggesting-22%-5%
PHS (diabetics sub group), 1989   aspirinplaceboLow risk of bias suggesting
WHS (diabetics sub group), 2005   aspirinplaceboLow risk of bias suggesting-7%
Physicians Health Study, 1989    NCTaspirinplaceboprimary preventionLow risk of bias suggesting -39%-17%
Thrombosis Prevention Trial, 1998        NCTaspirinplaceboprimary preventionLow risk of bias suggesting-32%-12%
HOT, 1998     aspirinplaceboprimary preventionLow risk of bias suggesting -40%-14%
Women’s Health Study, 2005       aspirinplaceboprimary preventionLow risk of bias suggesting 2%-9%
AAA, 2009     aspirinplacebosecondary preventionLow risk of bias negative
ASPREE, 2018    NCTaspirinplacebo -
ASCEND, 2018      NCTaspirinplacebosuggesting -12%
Schoop, 1983   aspirinplaceboLow risk of bias -
Hess, 1985   aspirinplacebo -
Munich A, 1975   aspirinplaceboLow risk of bias -
Munich B, 1975   aspirinplaceboLow risk of bias -
CLIPS, 2007     aspirinplaceboLow risk of bias suggesting-100%
CDPA, 1976   aspirinplaceboLow risk of bias negative-11%
Cardiff I, 1974   aspirinplaceboLow risk of bias negative
Cardiff II, 1979   aspirinplaceboLow risk of bias negative
Vogel, 1979   aspirinplaceboLow risk of bias suggesting-53%
AMIS, 1980    NCTaspirinplaceboLow risk of bias suggesting-22%
GAMIS, 1980   aspirinplaceboLow risk of bias negative-29%
PARIS, 1980   aspirinplaceboLow risk of bias negative-30%
JAMIS, 1999     aspirinplacebosuggesting-73%
SAPAT, 1992   aspirinplaceboLow risk of bias suggesting-33%-29%
clopidogrel
CAPRIE, 1996   clopidogrelaspirinsecondary preventionLow risk of bias suggesting-16%-8%
CAPRIE (PAD subgroup), 1996   clopidogrelaspirinLow risk of bias suggesting-33%
ASCET    NCTclopidogrelaspirinRisk of bias negative-10%
CHARISMA, 2006      NCTclopidogrelplacebo (on top aspirin)secondary preventionLow risk of bias suggesting -8%-7%
dipyridamol
Atlanta (Sbar), 1967   dipyridamolcontrolLow risk of bias negative-25%25%
Becker, 1967   dipyridamolcontrolLow risk of bias negative+Infini%
Wirecki, 1967   dipyridamolcontrolLow risk of bias negative
Hess (2), 1985   aspirin + dipyridamolplaceboLow risk of bias -
Schoop (2), 1983   aspirin + dipyridamolplaceboLow risk of bias -
VA study, 1986   aspirin + dipyridamolplaceboLow risk of bias -
Igloe, 1970   dipyridamolplaceboLow risk of bias -
Zion, 1961   dipyridamolplaceboLow risk of bias -
Kinsella, 1962   dipyridamolplaceboLow risk of bias -
Leiberman, 1964   dipyridamolplaceboLow risk of bias -
Dewar, 1961   dipyridamolplaceboLow risk of bias -
Neumann, 1964   dipyridamolplaceboLow risk of bias -
Foulds, 1960   dipyridamolplaceboLow risk of bias -
PARIS, 1980   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS-II, 1986   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS, 1980   dipyridamol + aspirinaspirinLow risk of bias negative
ketanserine
PACK, 1996   ketanserineplaceboLow risk of bias -
Walden, 1991   ketanserineplaceboLow risk of bias -
Thulesius, 1987   ketanserineplaceboLow risk of bias -
picotamide
Cocozza, 1995     picotamideplaceboLow risk of bias negative-100%-100%
ADEP, 1993   picotamideplaceboLow risk of bias -
Neirotti, 1994   picotamideplaceboLow risk of bias -
Coto, 1989   picotamideplaceboLow risk of bias -
sulfinpyrazone
Dutch, 1980   sulfinyrazoneplacebonegative107%
suloctidil
Adriaensen, 1976   suloctidilplaceboLow risk of bias -
Verhaeghe, 1981   suloctidilplaceboLow risk of bias -
Jones, 1982   suloctidilplaceboLow risk of bias -
Holm, 1984   suloctidilplaceboLow risk of bias -
ticagrelor
EUCLID, 2016        NCTticagrelorclopidogrelLow risk of bias -
PEGASUS 60mg, 2015        NCTticagrelorplacebo (on top aspirin)secondary preventionLow risk of bias suggesting -15%
PEGASUS 90mg, 2015        NCTticagrelorplacebo (on top aspirin)secondary preventionLow risk of bias suggesting